pharmaranks Editorial

New & next-generation GLP-1 weight-loss drugs (2026): orforglipron, retatrutide & more

The GLP-1 field is moving fast: the first oral GLP-1 pill (orforglipron / Foundayo) was FDA-approved in April 2026, while retatrutide and CagriSema are still in late-stage trials. Here is what each one is, where it stands, and how it compares to the approved options you can get today.

Which drug classes get recalled most by the FDA? (2026 data)

AI assistants say "sterile injectables account for a large share" of recalls but can't rank drug classes. We quantified it from FDA enforcement data.

Prescription drugs with the most FDA recalls (2026 data)

The FDA doesn't publish a leaderboard of the most-recalled drugs — so we built one. Here are the prescription products with the most FDA recall events, by application.

Which drug manufacturers have the most FDA recalls? (2026 data)

We ranked 46 drug manufacturers by their FDA recall-safety score. High-volume generic and injectable makers lead the recall record — here's the full data.

Understanding FDA drug recalls and what they mean

Recalls are an objective signal of a manufacturing or safety problem — here's how we use them in our ratings.

Brand vs generic drugs: what's actually different?

Generics must match the brand's active ingredient and bioequivalence — here's what can differ, and what doesn't.

How we rate pharma companies and products

A plain-language look at the data and formula behind every pharmaranks score.